ArticleVeterinary ophthalmology2026
Topical Mitomycin C Chemotherapy After Surgical Resection of Conjunctival Amelanotic Melanoma in a Dog.
Article in Veterinary ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the clinical course and outcome of adjuvant topical mitomycin C (MMC) therapy following incomplete resection of a conjunctival amelanotic melanoma in a dog. ANIMALS STUDIED: A 15-year-old spayed-female Shih Tzu presented with a conjunctival mass in the right eye (OD).
methodsOphthalmic and physical examinations, along with computed tomography results, confirmed that the tumor was confined to the conjunctiva and showed no systemic metastases. However, the mass had spread throughout the bulbar conjunctiva and third eyelid OD. A conjunctival mass involving the bulbar conjunctiva and the bulbar surface of the third eyelid of the OD was surgically debulked after the owners declined exenteration.
resultsHistopathology and immunohistochemistry confirmed malignant amelanotic melanoma with incomplete surgical margins. Adjuvant topical chemotherapy with 0.04% MMC ophthalmic solution was administered four times daily for one month following conjunctival healing. During topical MMC therapy, superficial corneal epithelial defects and conjunctival hyperemia developed, which resolved after discontinuation of the medication. Reduced tear production was noted during long-term follow-up and was managed with topical cyclosporine. No clinical evidence of local tumor recurrence was observed during the 14-month postoperative follow-up period, based on physical and ophthalmic examinations.
conclusionIn this case of conjunctival amelanotic melanoma with incomplete surgical excision, adjuvant topical MMC therapy was associated with the absence of clinically detectable local recurrence during long-term follow-up. Topical MMC may represent a potential globe-preserving adjuvant treatment option in selected cases of incompletely excised conjunctival melanoma; however, further studies are required to better define its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.